Male or female patients age 18 years or older, with relapsed or refractory sALCL who have previously received at least 1 multiagent chemotherapy
Bidimensional measurable disease
An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Female patients who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to practice true abstinence
Male patients who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence
Clinical laboratory values as specified in the study protocol

NCT01909934_inc_T1
Person
Male
NCT01909934_inc_T2
Person
female
NCT01909934_inc_T3
Person
age
NCT01909934_inc_T4
Value
18 years or older
NCT01909934_inc_T5
Condition
sALCL
NCT01909934_inc_T6
Qualifier
refractory
NCT01909934_inc_T7
Qualifier
relapsed
NCT01909934_inc_T8
Multiplier
at least 1
NCT01909934_inc_T9
Procedure
chemotherapy
NCT01909934_inc_T10
Scope
relapsed or refractory
NCT01909934_inc_T12
Measurement
stern Cooperative Oncology Group ( rformance status o
NCT01909934_inc_T13
Measurement
ECOG
NCT01909934_inc_T14
Value
0 or 1